These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37225485)

  • 21. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Yang L; Lai X; Yang T; Lu Y; Liu L; Shi J; Zhao Y; Wu Y; Chen Y; Yu J; Xiao H; Ouyang G; Ren J; Cao J; Hu Y; Tan Y; Ye Y; Cai Z; Xu W; Huang H; Luo Y
    Bone Marrow Transplant; 2024 Jan; 59(1):85-92. PubMed ID: 37907756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Donor Lymphocyte Infusion (DLI) post allogeneic stem cell transplant (allo-SCT) in Acute Myeloid Leukemia (AML) and High-Grade Myelodysplastic Syndrome (MDS). A longitudinal retrospective study using peripheral blood (PB) CD34
    Indran T; Das T; Muirhead J; O'Brien M; Swain MI; Cirone B; Widjaja J; Patil S; Curtis DJ
    Leuk Res; 2024 Jul; 142():107504. PubMed ID: 38703634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease.
    Stadler M; Hambach L; Dammann E; Diedrich H; Kamal H; Hamwi I; Schultze-Florey C; Varvenne M; Ehrlich S; Buchholz S; Koenecke C; Beutel G; Weissinger EM; Krauter J; Eder M; Hertenstein B; Ganser A
    Ann Hematol; 2023 Sep; 102(9):2529-2542. PubMed ID: 37490114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Efficacy of the MDS Patients Treated by Allo-HSCT].
    Wang QY; Dong YJ; Wang Q; Liu W; Sun YH; Yin Y; Liang ZY; Xu WL; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):172-180. PubMed ID: 33554815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occurrence and Severity of Donor Lymphocyte Infusion-Associated Chronic Graft-versus-Host Disease Influence the Clinical Outcomes in Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Yu WJ; Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2019 May; 25(5):912-920. PubMed ID: 30485788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
    Eefting M; von dem Borne PA; de Wreede LC; Halkes CJ; Kersting S; Marijt EW; Veelken H; Falkenburg JF
    Haematologica; 2014 Apr; 99(4):751-8. PubMed ID: 24241493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
    Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
    Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.
    Liberatore C; Stanghellini MTL; Lorentino F; Vago L; Carrabba MG; Greco R; Marktel S; Assanelli A; Farina F; Corti C; Bernardi M; Peccatori J; Sockel K; Middeke JM; Schetelig J; Bergmann A; Rautenberg C; Ciceri F; Bornhäuser M; Schroeder T; Stölzel F
    Ther Adv Hematol; 2022; 13():20406207221090882. PubMed ID: 35747461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy analysis of unrelated donor hematopoietic stem cell transplantation for treatment of high risk acute myeloid leukemia].
    Ye F; Tang XW; Sun AN; Qiu HY; Jin ZM; Fu ZZ; Chen F; Wu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):696-701. PubMed ID: 23815925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical efficacy of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome-evolved acute myeloid leukemia].
    Chen SL; Shi YY; Zhang LN; Gong M; Zhang XY; Zhao XL; Hao MZ; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
    Zhonghua Xue Ye Xue Za Zhi; 2024 Apr; 45(4):364-369. PubMed ID: 38951064
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].
    Liu W; Li Y; Qiu ZX; Yin Y; Sun YH; Xu WL; Wang Q; Liang ZY; Dong YJ; Wang LH; Cen QN; Wang MJ; Wang WS; Ou JP; Ren HY
    Zhonghua Nei Ke Za Zhi; 2018 Aug; 57(8):576-581. PubMed ID: 30060329
    [No Abstract]   [Full Text] [Related]  

  • 35. Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy.
    Zuanelli Brambilla C; Lobaugh SM; Ruiz JD; Dahi PB; Goldberg AD; Young JW; Gyurkocza B; Shaffer BC; Ponce DM; Tamari R; Sanchez Escamilla M; Castillo Flores N; Politikos I; Scordo M; Shah GL; Cho C; Lin RJ; Maloy MA; Devlin SM; Jakubowski AA; Berman E; Stein EM; Papadopoulos EB; Perales MA; Tallman MS; Giralt SA; Smith M
    Transplant Cell Ther; 2021 Sep; 27(9):771.e1-771.e10. PubMed ID: 34033977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Efficacy and Safety of Allogeneic Hematopoietic Stem Cell Transplantation with Decitabine-containing Regimen in Myelodysplastic Syndromes and Myelodysplastic Syndromes Transformed Acute Myeloid Leukemia].
    Wang YX; Sun Y; Xie J; Liu N; Hu JW; Qiao ZQ; Lan SC; Zhao L; Yang Y; Li YH; Zhang B; Hu LD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):522-531. PubMed ID: 37096529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
    Schroeder T; Stelljes M; Christopeit M; Esseling E; Scheid C; Mikesch JH; Rautenberg C; Jäger P; Cadeddu RP; Drusenheimer N; Holtick U; Klein S; Trenschel R; Haas R; Germing U; Kröger N; Kobbe G
    Haematologica; 2023 Nov; 108(11):3001-3010. PubMed ID: 37259567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing post allograft relapse of myeloid neoplasms: azacitidine and donor lymphocyte infusions as salvage therapy.
    Claiborne J; Bandyopathyay D; Roberts C; Hawks K; Aziz M; Simmons G; Wiedl C; Chung H; Clark W; McCarty J; Toor A
    Leuk Lymphoma; 2019 Nov; 60(11):2733-2743. PubMed ID: 31046498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Takami A; Yano S; Yokoyama H; Kuwatsuka Y; Yamaguchi T; Kanda Y; Morishima Y; Fukuda T; Miyazaki Y; Nakamae H; Tanaka J; Atsuta Y; Kanamori H
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1785-90. PubMed ID: 25034960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
    Davies JK; Hassan S; Sarker SJ; Besley C; Oakervee H; Smith M; Taussig D; Gribben JG; Cavenagh JD
    Br J Haematol; 2018 Feb; 180(3):346-355. PubMed ID: 29076145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.